JP2012224636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012224636A5 JP2012224636A5 JP2012166700A JP2012166700A JP2012224636A5 JP 2012224636 A5 JP2012224636 A5 JP 2012224636A5 JP 2012166700 A JP2012166700 A JP 2012166700A JP 2012166700 A JP2012166700 A JP 2012166700A JP 2012224636 A5 JP2012224636 A5 JP 2012224636A5
- Authority
- JP
- Japan
- Prior art keywords
- glucan
- conjugate according
- conjugate
- laminarin
- bacterial toxoid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims 21
- 229920002498 Beta-glucan Polymers 0.000 claims 19
- 229920001503 Glucan Polymers 0.000 claims 5
- 230000001580 bacterial effect Effects 0.000 claims 5
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 claims 4
- 229920001543 Laminarin Polymers 0.000 claims 4
- 239000005717 Laminarin Substances 0.000 claims 4
- 230000002538 fungal effect Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 102100024023 Histone PARylation factor 1 Human genes 0.000 claims 1
- 101001047783 Homo sapiens Histone PARylation factor 1 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 244000053095 fungal pathogen Species 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0211118.5 | 2002-05-15 | ||
| GBGB0211118.5A GB0211118D0 (en) | 2002-05-15 | 2002-05-15 | Vaccines |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009294467A Division JP2010131017A (ja) | 2002-05-15 | 2009-12-25 | グルカンベースのワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012224636A JP2012224636A (ja) | 2012-11-15 |
| JP2012224636A5 true JP2012224636A5 (https=) | 2013-07-18 |
| JP5684758B2 JP5684758B2 (ja) | 2015-03-18 |
Family
ID=9936711
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505087A Expired - Fee Related JP5110767B2 (ja) | 2002-05-15 | 2003-05-15 | グルカンベースのワクチン |
| JP2009294467A Pending JP2010131017A (ja) | 2002-05-15 | 2009-12-25 | グルカンベースのワクチン |
| JP2012166700A Expired - Fee Related JP5684758B2 (ja) | 2002-05-15 | 2012-07-27 | グルカンベースのワクチン |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505087A Expired - Fee Related JP5110767B2 (ja) | 2002-05-15 | 2003-05-15 | グルカンベースのワクチン |
| JP2009294467A Pending JP2010131017A (ja) | 2002-05-15 | 2009-12-25 | グルカンベースのワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20050208079A1 (https=) |
| EP (2) | EP1891970B1 (https=) |
| JP (3) | JP5110767B2 (https=) |
| AT (2) | ATE395080T1 (https=) |
| AU (1) | AU2003241104A1 (https=) |
| CA (2) | CA2485847C (https=) |
| CY (1) | CY1108234T1 (https=) |
| DE (2) | DE60336027D1 (https=) |
| DK (1) | DK1506009T3 (https=) |
| ES (1) | ES2306871T3 (https=) |
| GB (1) | GB0211118D0 (https=) |
| PT (1) | PT1506009E (https=) |
| SI (1) | SI1506009T1 (https=) |
| WO (1) | WO2003097091A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| ATE508362T1 (de) * | 2004-04-05 | 2011-05-15 | Univ Bordeaux 2 | Peptide und peptidmimetika die an cd23 binden |
| GB0420466D0 (en) * | 2004-09-14 | 2004-10-20 | Cassone Antonio | Anti-glucan antibodies |
| US8398983B2 (en) | 2005-06-27 | 2013-03-19 | Glaxosmithkline Biologicals, S.A. | Immunogenic composition |
| US8323644B2 (en) * | 2006-01-17 | 2012-12-04 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
| EP1984004A4 (en) * | 2006-01-17 | 2010-03-03 | Sloan Kettering Inst Cancer | THE THERAPY REINFORCING GLUCAN |
| US20090053221A1 (en) * | 2006-01-17 | 2009-02-26 | Cheung Nai-Kong V | Immune response enhancing glucan |
| WO2007127668A2 (en) * | 2006-04-26 | 2007-11-08 | Wyeth | Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations |
| AU2013203785B2 (en) * | 2006-11-06 | 2016-11-17 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| JP6082174B2 (ja) * | 2006-11-06 | 2017-02-15 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | 免疫調節組成物及びその使用方法 |
| US9457047B2 (en) | 2006-11-06 | 2016-10-04 | Whitehead Institute | Immunomodulating compositions and methods of use thereof |
| JP4687644B2 (ja) | 2006-12-22 | 2011-05-25 | 富士ゼロックス株式会社 | 画像処理装置、画像読取装置及び画像形成装置 |
| JP5572097B2 (ja) | 2007-11-26 | 2014-08-13 | ノバルティス アーゲー | 結合体化されたβ−１，３−結合グルカン |
| EP2227248B2 (en) † | 2007-11-26 | 2018-01-31 | GlaxoSmithKline Biologicals SA | Adjuvanted glucans |
| EP2283358B1 (en) * | 2008-04-29 | 2015-04-22 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| NZ591768A (en) | 2008-09-18 | 2012-11-30 | Novartis Ag | Vaccine adjuvant combinations |
| NL1036661C2 (en) | 2009-03-04 | 2010-09-07 | Serrix B V | Anti-fungal compounds & compositions. |
| WO2010103519A1 (en) * | 2009-03-10 | 2010-09-16 | Palmed Teva Ltd | Novel coprinus comatus and tremella mesenterica mushroom strains, products and extracts thereof and compositions comprising them |
| CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| WO2011035205A2 (en) | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
| PH12012502227A1 (en) * | 2010-05-14 | 2021-06-23 | Alltech Inc | Yeast cell wall components and detection thereof |
| ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| US9618508B2 (en) | 2010-12-14 | 2017-04-11 | Glaxosmithkline Biologicals Sa | Flow cytometry analysis of materials adsorbed to metal salts |
| WO2012117377A1 (en) | 2011-03-02 | 2012-09-07 | Novartis Ag | Combination vaccines with lower doses of antigen and/or adjuvant |
| WO2013009564A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | Tyrosine ligation process |
| EP2776069A1 (en) | 2011-11-07 | 2014-09-17 | Novartis AG | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| MX346678B (es) | 2012-03-07 | 2017-03-29 | Novartis Ag | Sales de arginina utiles inmunologicamente. |
| MX372965B (es) | 2012-03-08 | 2020-04-01 | Glaxosmithkline Biologicals Sa | Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo. |
| US11229701B2 (en) * | 2012-04-30 | 2022-01-25 | Hibercell, Inc. | Methods for identifying beta-glucan binding to immune cells |
| JP6411378B2 (ja) | 2013-02-01 | 2018-10-24 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達 |
| CN103083663B (zh) * | 2013-02-04 | 2014-12-10 | 江苏省农业科学院 | 一种免疫增强剂、灭活疫苗及其制备方法 |
| WO2014158963A1 (en) | 2013-03-12 | 2014-10-02 | Wellstat Vaccines, Llc | Antibodies targeted to fungal cell wall polysaccharides |
| EP3019515B1 (en) | 2013-07-11 | 2019-08-21 | Novartis AG | Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase |
| WO2015084732A1 (en) * | 2013-12-05 | 2015-06-11 | Biothera, Inc. | β-GLUCAN ASSAY METHODS |
| EP3862002A1 (en) * | 2015-01-26 | 2021-08-11 | Kaleido Biosciences, Inc. | Glycan therapeutics and related methods thereof |
| CN104771498A (zh) * | 2015-03-13 | 2015-07-15 | 臧海阳 | 一种治疗热毒蕴结型痄腮的中药组合物 |
| US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
| ES2960686T3 (es) | 2018-01-19 | 2024-03-06 | Miltenyi Biotec Bv & Co Kg | Células T reguladoras que expresan un receptor de antígeno quimérico |
| US11701417B2 (en) * | 2019-03-27 | 2023-07-18 | West Virginia University | Vaccine formulation to protect against pertussis |
| WO2023002252A1 (en) | 2021-07-21 | 2023-01-26 | Bioatlantis Limited | Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same |
| WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
| JP2025507875A (ja) | 2022-02-28 | 2025-03-21 | トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー | 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE466289B (sv) * | 1984-09-19 | 1992-01-27 | James Hoffman | Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning |
| JPS6383012A (ja) * | 1986-09-26 | 1988-04-13 | Nonogawa Shoji:Kk | 化粧料 |
| AU650626B2 (en) * | 1989-09-08 | 1994-06-30 | Alpha-Beta Technology, Inc. | Method for producing soluble glucans |
| EP0471954A3 (en) | 1990-08-13 | 1993-03-03 | American Cyanamid Company | Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide |
| US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
| DK0616034T3 (da) * | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid til fremstilling af CRM-protein og diphtheria toxin |
| CN1094288A (zh) * | 1993-04-23 | 1994-11-02 | 福建省微生物研究所 | 利用红色诺卡氏菌制造细胞壁骨架粉末的方法 |
| NO300692B1 (no) | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan |
| US6309642B1 (en) * | 1997-04-28 | 2001-10-30 | The Research And Development Institute, Inc. | Peptides which mimic candida carbohydrate epitopes and their use in a vaccine |
| AUPN166195A0 (en) | 1995-03-13 | 1995-04-06 | Norvet Research Pty Limited | Process for glucan extraction |
| JPH09309842A (ja) * | 1996-05-20 | 1997-12-02 | Kureha Chem Ind Co Ltd | 新規な生理活性物質、その製造方法及び医薬組成物 |
| CA2329897A1 (en) * | 1998-04-28 | 1999-11-04 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| JP4230635B2 (ja) | 2000-02-29 | 2009-02-25 | 富士フイルム株式会社 | デジタルカメラ |
-
2002
- 2002-05-15 GB GBGB0211118.5A patent/GB0211118D0/en not_active Ceased
-
2003
- 2003-05-15 AT AT03730424T patent/ATE395080T1/de active
- 2003-05-15 PT PT03730424T patent/PT1506009E/pt unknown
- 2003-05-15 AT AT07075796T patent/ATE497781T1/de not_active IP Right Cessation
- 2003-05-15 DK DK03730424T patent/DK1506009T3/da active
- 2003-05-15 ES ES03730424T patent/ES2306871T3/es not_active Expired - Lifetime
- 2003-05-15 AU AU2003241104A patent/AU2003241104A1/en not_active Abandoned
- 2003-05-15 DE DE60336027T patent/DE60336027D1/de not_active Expired - Lifetime
- 2003-05-15 SI SI200331275T patent/SI1506009T1/sl unknown
- 2003-05-15 CA CA2485847A patent/CA2485847C/en not_active Expired - Fee Related
- 2003-05-15 JP JP2004505087A patent/JP5110767B2/ja not_active Expired - Fee Related
- 2003-05-15 EP EP07075796A patent/EP1891970B1/en not_active Expired - Lifetime
- 2003-05-15 WO PCT/IB2003/002460 patent/WO2003097091A2/en not_active Ceased
- 2003-05-15 DE DE60320979T patent/DE60320979D1/de not_active Expired - Lifetime
- 2003-05-15 EP EP03730424A patent/EP1506009B1/en not_active Expired - Lifetime
- 2003-05-15 CA CA2830619A patent/CA2830619A1/en not_active Abandoned
- 2003-05-15 US US10/514,483 patent/US20050208079A1/en not_active Abandoned
-
2007
- 2007-02-01 US US11/701,250 patent/US7824688B2/en not_active Expired - Fee Related
-
2008
- 2008-07-31 CY CY20081100809T patent/CY1108234T1/el unknown
-
2009
- 2009-12-25 JP JP2009294467A patent/JP2010131017A/ja active Pending
-
2010
- 2010-08-11 US US12/854,248 patent/US8398990B2/en not_active Expired - Fee Related
-
2012
- 2012-07-27 JP JP2012166700A patent/JP5684758B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-26 US US13/777,903 patent/US8679506B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012224636A5 (https=) | ||
| WO2011028888A3 (en) | Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with an improved immunogenicity | |
| JP2010535814A5 (https=) | ||
| MX342684B (es) | Regimen de dosificacion escalante para efectuar la perdida de peso y el tratamiento de obesidad. | |
| EP2762165A3 (en) | Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof | |
| WO2009051837A3 (en) | Vaccine nanotechnology | |
| WO2009090670A8 (en) | Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same | |
| JP2010215657A5 (https=) | ||
| WO2007113222A3 (en) | Immunogenic composition | |
| WO2011156774A3 (en) | Multivalent glycopeptide constructs and uses thereof | |
| WO2009077854A3 (en) | Adjuvanted glucans | |
| WO2013052167A3 (en) | Membrane encapsulated nanoparticles and method of use | |
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| WO2007105115A3 (en) | Compositions and methods for immunisation using cd1d ligands | |
| JP2013502227A5 (https=) | ||
| IL210789A (en) | Susanimidyl 4-acetylsulfanyl butyrate, para-nitrophenyl 4-acetylsulfanyl butyrate, a method for synthesized oligosaccharide-bearing synthesis, an oligosaccharide-containing preparation, and an oligosaccharide-bore oligosaccharide pair | |
| WO2006126981A3 (en) | Compositions and methods for mucosal vaccination | |
| WO2006030318A3 (en) | PROTECTIVE ANTI-GLUCAN ANTIBODIES WITH PREFERENCE FOR β-1,3-GLUCANS | |
| WO2007084661A3 (en) | Therapy-enhancing glucan | |
| WO2011060372A3 (en) | Factor viii b cell epitope variants having reduced immunogenicity | |
| JP2008535798A5 (https=) | ||
| JP2008525311A5 (https=) | ||
| WO2013188627A3 (en) | Cationic lipid vaccine compositions and methods of use | |
| WO2008008541A8 (en) | Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes | |
| WO2011047837A3 (de) | Schmelzgranuliertes cinacalcet |